Aches and pains. A growing waistline. Diminishing eyesight, hearing loss, memory lapses. These are the woes of growing older for some people, once considered inevitable. But recent, exciting discoveries in the fast-growing field of longevity science have some doctors and researchers pronouncing that these symptoms of aging may one day be treatable with pharmaceuticals, gene therapies or other yet-to-be-discovered medical technologies.

Many people havent been content to wait, though. Dozens of commercial producers are selling hundreds of so-called longevity supplements right now, and sales data suggest anawful lot of peopleare trying them. But do they work? Are they even safe?

To find out, we scoured the latest research and interviewed two top scientists in the field. What we learned suggests that you may want to hold off on ordering a supply, or at least do your research very carefully.

There is a solid handful of compounds that look very promising in the scientific quest to slow the aging process. One of the most exciting is nicotinamide adenine dinucleotide, or NAD, which has been shown to extend both the lifespans and youthful function of yeast and animals in clinical trials. Human trials are ongoing, with only a handful published to date.

NAD (also often written as NAD+) is a substance found in every cell in your body, which controls all kinds of metabolic processes, including the regulation of sirtuins, the so-called longevity genes. As you age, your NAD+ levels decline, and scientists think it is perhapsthisdecline that leads toall sortsof other age-related declines.

Also read: Should you invest in the new longevity funds?

The working theory, then, is that if we can boost our NAD+ levels as we age, we can slow our decline tremendously. Lab studies on yeast and rodentslend strong supportto that theory. The most recent studies have primarily involved the administration of either nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), which is then converted into NAD in the body.

To learn more about NAD, Next Avenue talked to Dr. Shin-Ichiro Imai, professor of developmental biology at the Washington University School of Medicine in St. Louis. Along with Leonard Guarente, Imai discovered the link between NAD and sirtuin control in 1999. Hes been studying the molecule ever since.

There have been 10 human clinical trials using NR, most at very high dose, with no safety issues, Imai said. Most of those trials, however, lasted for a duration of weeks or months at most.

Is it safe to take NAD-boosting supplements continuously, for years?

NMN and NR have already been available in Japan and the U.S. since 2015, and some people have been taking it since then, Imai noted. Anecdotally, I havent heard of any side effects from the taking of these supplements.

Some trials, however, have recorded mild side effects including headaches, nausea, diarrhea and skin flushing.

See: 3 aging experts tell how they decided on where to grow older

More troubling, however, is the conclusion of a 2019 study that showed a possible link between elevated levels of NAD and tumor growth in isolated cells and animals. Rugang Zhang, deputy director at the nonprofit Wistar Institute Cancer Center in Philadelphia, was the lead researcher on that study.The study, published in the UK journal Nature Cell Biology, did not find that NAD causes cancer, rather that elevated levelsappeared to accelerateoncogenesis (tumor formation) already in motion.

We dont want to oversell the results of our study, Zhang said. Lots of studies in the literature have clearly demonstrated that as normal cells age, there is lower NAD. So, supplementing NAD could be beneficial. Its possible that NAD boosters could help people live longer and healthier. Were not saying that if people take NAD boosters they will get cancer. This was a very early study on mouse models, and more study is needed.

He suggests a course of action grounded in a deep preponderance of evidence: At the end of the day, we just need more knowledge, through more research. We need the scientific community to come to a consensus. The risk to potential benefit remains to be seen.

Mucking up the risk/benefit ratio further is the fact that supplements are onlyvery lightly regulatedby the U.S. Food and Drug Administration, with the testing, evaluation and labeling of such products left up to manufacturers. This presents another dilemma for those considering longevity supplements: theres no sure way of knowing exactly what youre getting.

The results of the few published human clinical trials to date unequivocally show that taking NR boosts levels of NAD in the body. But apparently, more NAD doesnt translate to more youthful function.

See: There are six types of retirees which are you?

Unfortunately, those studies have not yet shown any significant efficacy, Imai said.

And thats when the substance administered is of lab-grade purity. So what about the typical supplements available online?

There are so many products out there, Imai lamented, particularly for NMN, but Im concerned about the quality.

Indeed, a 2020meta-analysisof NAD trials surmised: it seems likely that side effects linked to interventions that target NAD metabolism more likely arise from impurities rather than the supplements themselves, since this industry generally operates without rigorous control of quality and standardization.

Imais lab has evaluated a number of commercially available NAD-boosting supplements, but found only two of lab-grade purity. Imai wouldnt disclose the names of the products (both Japanese-made), as he doesnt endorse supplements. But he did note that they are extremely expensive.

Dont miss: What is the secret to aging well?

Finally, we asked someone whod taken an NAD-booster to share her experience. Kim Oberdorfer, an air-traffic controller in Oakland, Calif., wasnt impressed.

I took [a popular NR supplement] for about two months and it just gave me these dull headaches. I was having hot flashes last February, and when I told my sister Im 47, shes 53 about how horrified I was to be having them so young, she goes, Are you sure its not just a reaction to an NAD supplement? said Oberdorfer. At the time I wasnt really working out much, but my sleep schedule was really messed up and I heard it was good for that as well. I didnt think it helped at all.

Rashelle Brownis a longtime fitness professional and freelance writer with hundreds of bylines in print and online. She is a regular contributor for NextAvenue and the Active Network, and is the author of Reboot Your Body: Unlocking the Genetic Secrets to Permanent Weight Loss (Turner Publishing). Connect with her on Twitter and Instagram @RashelleBrownMN.

This article is reprinted by permission fromNextAvenue.org, 2021 Twin Cities Public Television, Inc. All rights reserved.

More from Next Avenue:

Here is the original post:
What are longevity supplements, and are they safe? - MarketWatch

PITTSBURGH, Dec. 30, 2020 /PRNewswire/ --LyGenesis, Inc., a biotechnology company developing cell therapies that enable organ regeneration, announced today that the U.S Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application.Under the IND, LyGenesis will be conducting a Phase 2a study on the safety, tolerability, and efficacy of its first-in-class novel cell therapy for patients with end stage liver disease (ESLD).

In addition, LyGenesis just completed over $11 million in private financing of convertible notes led by Juvenescence, Ltd. and Longevity Vision Fund. Proceeds will be used to fund LyGenesis's Phase 2a clinical trial with a first patient in targeted for early 2021, as well as to push forward on their other cell therapies using lymph nodes as bioreactors to regrow functioning organs, including pancreas, kidney, and thymus regeneration.

"The FDA clearance for our IND and the start of our Phase 2a study in patients with ESLD is a testimony to our robust preclinical research program, the unmet need in advanced liver disease, and our novel approach to organ regeneration. Moreover, the lack of genetic manipulation, ease of administration, and low cost of goods for our cell therapy forms the foundation for a promising and scalable first commercial product," said Michael Hufford, PhD, Co-Founder and CEO of LyGenesis.

"LyGenesis's progress has been simply extraordinary. They have recently published 4 peer-reviewed papers on their regenerative medicine technology, filed and received clearance for their first IND, identified a primary site for their Phase 2a clinical trial, and now have closed a round of financing to ensure they have the cash to run their trial and also progress additional cell therapies toward the clinic," said Jim Mellon, Co-Founder of Juvenescence, and Chair of LyGenesis's Board of Directors. Sergey Young, founder of Longevity Vision Fund, said "We are excited to support LyGenesis in its vision to tackle some of the most challenging unmet medical needs of our time with a unique organ regeneration technology. By enabling one donated organ to act as a source of therapies for dozens of patients, LyGenesis is on the cusp of disrupting the supply-demand calculus of organ donation, and this regulatory clearance from the FDA is a definitive milestone in their evolution."

About LyGenesis, Inc.LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient's lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis's lead allogeneic cell therapy program is focused on liver regeneration for patients with end stage liver disease. Its drug development pipeline includes thymus, pancreas, and kidney regeneration. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.

About Juvenescence, Ltd.Juvenescence Ltd. is a life sciences company developing therapies to modify aging increasing human health span and longevity. It was founded byJim Mellon,Dr. Gregory BaileyandDr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the pharmaceutical and consumer health sectors. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging. To learn more, please visit juvlabs.com.

About Longevity Vision FundLongevity Vision Fund is a venture capital fund that invests in technologies with the potential to disrupt life sciences to help people live longer and healthier lives. The fund is focused on early diagnostics, AI in healthcare, and advanced therapeutic platforms targeting aging and age-related diseases. It was founded by Sergey Young, a venture capital investor with a mission to make longevity more accessible and affordable. Sergey is also an Innovation Board member at XPRIZE Foundation and a development sponsor of Age Reversal XPRIZE. To learn more, please visit lvf.vc.

Contact InformationMichael Hufford(858) 603-2514[emailprotected]

SOURCE LyGenesis, Inc.

Read the original post:
LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million...

PLEASANT HOPE, Mo. A beef processing plant in the process of being built in Pleasant Hope, Missouri, is looking to hire job seekers to work in its 100,000 square foot facility.

Pam Johnson, the director of human resources, said she is working with Missouri Prime Beef Packers to figure out what kind of employees it wants working in its facility.

Here we focus on doing the right thing: for the employee, the animal, the consumer, Johnson says. We are going to take care of our team members. The owners and management team have fully embraced the show me culture, and they want to show current and potential team members that they will be taken care of. We are offering great pay and benefits as well as continued encouragement to improve and learn new skills. As people strive to grow, they will be rewarded.

The plant will have the capacity to process up to 500 cows per day, but director of operations Mike Schmeling said their focus is more on quality.

We are not a big plant that is solely focused on the number of head processed per hour, said Schmeling. We are flexible. We can respond to market changes, consumer demands, or other unexpected factors like COVID-19 as well as, if not better than, anyone in the industry.

Nick Paschkov, COO of Missouri Prime Beef Packers, hopes for the plant to positively impact the community.

The ownership has shown their commitment to the longevity and success of this plant by empowering us to use our experience to design a state-of-the-art beef processing plant that will be a model for future facilities, Paschkov states. This company emphasizes food and employee safety and product quality over volume production, and our design accounts for that.

The construction phase of the plant is underway to process both fed and non-fed beef cattle. Missouri Prime Beef said its searching for people who can supply cows and buy products along with those seeking employment.

Those interested can look at Missouri Prime Beefs website or call 417-462-6727.

Originally posted here:
Pleasant Hope facility looking to hire people to work in beef processing plant - KOLR - OzarksFirst.com

FERNANDINA BEACH, Fla., Dec. 9, 2020 /PRNewswire/ -- Ponce De Leon Health, Inc. ("Ponce de Leon"), a longevity research company focused on the reversal of epigenetic aging, announced today that Brian Kennedy, Ph.D., will speak at the SupplySide Network "Healthy Aging Never Gets Old" event on December 10th, 2020, at 1:00 PM Eastern.Doctor Kennedy is currently serving as Director of the Centre for Healthy Longevity, at the National University of Singapore.Registration for this free event can be found on theSupplySide Network 365platform.

Doctor Kennedy was invited to address industry leaders to discuss recent research which led to the development of Rejuvant LifeTabs, a dietary supplement designed for healthier aging. Informa Health & Nutrition named Rejuvant LifeTabs asthe top Consumer Packaged Goods winner in the Best Life-Span Specificcategory, at the 2020 NEXTY SupplySide Awards. According to Informa, Rejuvant contains "a ground-breaking ingredientLifeAKGand a meticulously researched, time-release formula tailored to men and women."

This news follows on the heels of Ponce De Leon Health announcement in September with the first peer-reviewed study of a non-drug substance demonstrating improvements in mammalian lifespan, reduction in frailty, and reduction in time of suffering. The results of the research were published in the September 1, 2020 issue of the journal Cell Metabolism. The researchers found that LifeAKG "promotes longer, healthier life associated with a decrease in levels of inflammatory cytokines. Strikingly, the reduction in frailty led the scientists to "propose that Ca-AKG compresses the period of morbidity." The publication, titled "Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice," and was authored by Azar Shamirzadi, Ph.D., et al., and directly led to the development of Rejuvant LifeTabs.

Tom Weldon, the CEO and Founder of Ponce De Leon Health, remarked, "We're very proud of our research, past and ongoing, and committed to reversing epigenetic aging. Our product, Rejuvant LifeTabs, is emblematic of the growing discoveries in the field of epigenetics, or the changes made by modification of gene expression.We continue to conduct new human and animal trials to better demonstrate the benefits of Rejuvant on biological aging, healthspan and lifespan."

Todd Runestad, Senior Editor of Ingredients and Supplements, New Hope Media and Natural Products Insider, invited Dr. Kennedy to speak at the event.Said Mr. Runestad, "healthy aging is a prime consideration of supplement usersfrom specific health conditions like bone or joint or cognitive health, to the more general concept of aging gracefully. Of course, people have long sought out skin-health products, but the new frontier is the provocative research around epigenetics and nutrigenomicsthat one's lifespan is not just predicated on genetics, but that gene expression can be modulated by diet and specific dietary supplements."

Mr. Runestad added, "Brian Kennedy has been researching such concepts for decades now. He is one of the world's leading anti-aging researchers, and he may have come up with this decade's resveratrolthe fountain of youth molecule found in red wine. We awarded a NEXTY award for the year's best innovation, integrity and inspiration, to a supplement brand Dr. Kennedy helped develop for Ponce de Leon Health. The company's Rejuvant LifeTabs, coupled with an in-home genetic test kit, allows consumers the ability to actually track over time genetic markers of aging while taking the supplement. Personalized health care meets anti-aging science."

About Ponce De Leon HealthPonce De Leon Health (www.PDLHealth.com) is a commercial-stage longevity company focused on the discovery, development and commercialization of non-prescription consumer products to address the reversal of epigenetic aging. Their goal is to increase human healthspan, improve quality of life, and reduce the cost of providing late stage health care to customers.

To learn more about the groundbreaking science behind Rejuvant LifeTabsvisit http://www.rejuvant.com or follow @rejuvanthealth(Facebook), @Rejuvant (Twitter), or Ponce De Leon Health (YouTube).

SOURCE Ponce De Leon Health

http://pdlhealth.com

Go here to see the original:
Leading Healthy Aging Researcher Brian Kennedy, Ph.D., To Address Natural Health Industry On Impact Of Nutrition On Biological Age - PRNewswire

During the holidays, fasting may be the furthest thing from your mind. Once the Holidays are over, however, it may suddenly seem like an attractive option. Eating, as a basic activity of daily living, compensates for feelings of hunger and provides necessary nutrients to our physiological systems. Moreover, what we eat and how we eat can play a significant role in our health and well-being and may even impact longevity. Because of the significance of eating on well-being, diet interventions receive extensive attention in the media. Among different types of dietary interventions, fasting is emerging as the most significant; current research suggests that changing ones eating habits by reducing caloric intake, when coupled with modifying meals schedules may delay or prevent the onset of many types of diseases and extend years of functionality to cells, tissues and organs.

Dr. Valter Longo, director of the USC Longevity Institute, has done numerous studies supporting the positive effects of fasting on longevity. The rationale of fasting to improve health can be explained, in part, by the Disposable Soma Theory, a major theory in physiology of aging studies. This theory posits that the notion of senescence is the decrease in an organisms ability to reproduce and causes a related increase in the chances it will die as it ages. It assumes that the body needs to budget and appropriate the energy for various tasks to maintain subsistence. In allocating energy for different physiological activities, there is a tradeoff between using it for reproduction or for cell, tissue or organ repair.

In other words, if a substantial proportion of available energy is used for growing new tissues, less energy will remain for reproduction, regeneration and repair of existing body components. When we eat less food, our systems may interpret this behavior as a signal that the energy acquired from digesting food is becoming scarce. Therefore, our body will adjust so as not to deplete remaining energy by using too much of the it for reproductive activities. Instead, the body will focus more on maintaining the function of existing tissues and wait for a more suitable time to reproduce. As a result, existing tissues will be better maintained and protected. In maintenance mode, our body systems, tissues and organs will be kept strong and healthy. That is a general explanation on how fasting can reduce morbidity and contribute to longevity.

Fasting refers to purposefully restricting ones diet for a specific period. Traditionally, fasting was practiced in the manner of continuous caloric restriction, but the development of clinical trials and carefully designed programs have enriched our understanding of the effects of calorie-restricted fasting. Andrea Di Francesco, Clara Di Germanio, Michel Bernier, and Rafael de Cabo (2018) categorized fasting in four domains:

Human beings have practiced fasting and the unpleasant variance we know as starvation. However, because of their using unsophisticated medical technologies, the potential health benefits of fasting were not noted adequately. Today, fasting is receiving more attention and current scientific, social and economic developments make the health and beauty effects of fasting more attractive to consider. We have basic recommendations for those who may be considering one of these fasting options:

First, when deciding to practice fasting, take the time to do some research on possible negative outcomes. This will enhance your health literacy regarding fasting and possible consequences.

Second, before beginning a program of fasting, consult with a professional nutritionist on how best to proceed. For people who have no experience in fasting, suddenly being deprived of certain foods may be challenging; therefore, it is necessary to take a strategic approach to dieting to improve the odds of achieving diet goals.

Third, if it becomes impossible to tolerate the dietary restrictions, feel free to give up and restart when further motivated. The first few days of fasting could be difficult to bear. If the uncomfortable feelings have exceeded our level of tolerance, we should not feel guilty. Sometimes, ones own body may recognize that to continue fasting may result in unintentional, negative consequences to our health and well-being. Often, we can back off for a period and restart fasting when we are so inclined.

Remember that unless approached systematically, after undertaking weight-loss dieting, the weight lost often comes back and, even worse, additional pounds may accrue without carefully maintaining diet guidelines.

If you have questions, or comments about this article, please contact the authors at usc.rxxlab@gmail.com.

Disclaimer: Persons with eating disorders should consult with a physician before considering any fasting diet.

Mengzhao Yan, MA, Senior Lab Assistant; Erin Crutcher, MSG Candidate, Research Assistant; George Shannon, MSG, PhD; Director, USC Rongxiang Xu Regenerative Life Science Lab (RxX Lab).

More:
Fasting to Enhance Longevity? - L.A. Weekly

Published December 11, 2020 by Ruth Comerford

Welbeck Childrens has announced a new partnership with environmentcharity and non-profit organisationthe National Forest,as it prepares to publish non-fictionpicture bookWhat Did the Tree See?by Charlotte...

Welbeck Childrens has announced a new partnership with environmentcharity and non-profit organisationthe National Forest, as it prepares to publish non-fiction picture bookWhat Did the Tree See? by Charlotte Guillain, illustrated by Sam Usher, in the new year.

The partnership will see a percentage of the book's sales goto the National Forest, to support its woodland creation and management programmes. The National Forest isgrowing trees across 200 square miles of the Midlands. It is the first forest to be created at scale in England for over 1,000 years.

Told in rhyming verse, What Did the Tree See? follows the story of an oak tree on a hilltop as it witnesses life changing around it over the course of hundreds of years, from the time when hunters chased deer through the woodland, to when trees were cleared for farmland, to the smog and factories emerging during the Industrial Revolution. Accompanying pages at the end of the book include a timeline of events in world history across the periods featured in the poem,the lifecycle of an oak tree, and prompts to help parents and children explore their own local history.

Partnership activities will include schools engagement and promotion of experiences that encourage families and schools to visit the forest, or explore their local woodlands while sharing the books messages, such as finding out if there is a project to plant more trees where they live or watching trees grow through the changing seasons.

Welbeck Childrens will be providing the National Forest with supporting resources, including activity packs and a digital poster.

David Bourque, director of development at the National Forest, said:"We are delighted to be partnering with Welbeck Childrens and its beautiful new title What Did the Tree See?. The book highlights the longevity and power of some of our most special trees and how fragile the balance is between the environment and human development. We need to make sure we get that balance right for the next generation. In terms of publishing, Welbeck Childrens use of FSC paper and soy inks reflect how their industry is innovating in response to climate change something we want to see more of at the National Forest."

Jane Harris, childrens group publisher, said: "Our partnership with the National Forest is part of a broader commitment to sustainability for Welbeck Publishing. It is exciting to be able to support such a great cause with this beautiful new book for children."

What Did theTree See?will be published on18th February 2021.

The rest is here:
Welbeck Children's partners with National Forest - The Bookseller

December is bringing frost in the North and plenty of cold hard cash for these life sciences companies.

Forbion

European venture capital firmForbionrounded up$545 millionfor its fifthlife sciences fund. Investments will be made in about 15 therapeutics companies, with a third created byForbionthrough its Build opportunities. The rest will be invested in highly impactful existing companies.With offices in the Netherlands, Germany and Singapore, theplan is to invest about 80% into Europeancompanies and the rest in North American startups.

AbCellera

Since partnering with Eli Lilly to produce the first monoclonal antibody therapyapprovedfor mild-to-moderate COVID-19 patients,antibody discovery companyAbCellerais going big on the Nasdaq. Offering 23 million shares between $14-$17 apiecefor a hopeful total of$391 million, the company is lining up the biggest debut on record for a Canadian biotech.AbCellerasAI-powered antibody discovery platform speeds theotherwise lengthy and gruelingprocessby analyzing the database of natural immune systems to findantibodies that canbe developed into drugs.Thepromiseto partners is to move quickly. Reduce cost. Tackle the toughest problems in drug development. Investors include big names like Peter Thiel, Bill and Melinda Gates Foundation and more.

Silverback Therapeutics

Silverback goes for gold, upping its IPO for a4thtimesince the initial announcement. Originally slated for $125 million,the biotech is now shooting for a$241 millionraise by offering 11.5 million shares at $21 each. Some of the funds will be used for thedevelopment of therapeutics for oncology and other serious diseases through its proprietaryImmunoTACtechnology platform.TheImmunoTACplatform pairs proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Silverbacks lead candidate is currently in a Phase I trial in adults with HER2-expressing solid tumors.

Nuance Pharma

Theres nothing subtle about Nuances$181 millionSeries D financing round. The fully integrated pharmaceutical company creates value through Chinas specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory.Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets.

SigilonTherapeutics

Now live on the ticker,Sigilonhopes to sell 7 million shares fora$126 millionraise.Through its Shielded Living Therapeutics platform, the company is developing functional cures for chronic diseases. The companysproduct candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. The engineered cells are protected bySigilonsAfibromer biomaterials matrix, which shields them from immune rejection and fibrosis. In March, the company closed an $80.3 million Series B.

RayzeBio

Launched in October with a$45 million Series A,RayzeBioput a Series B on their Christmas list and Santa came early.With a pipeline of targeted radiopharmaceuticals against validated solid tumors, the biotech looks toutilizethe$105 millionraise into advancing their programs toward the clinic.Thecompanys goal is focused on improving outcomes for cancer patients by harnessing the power of targeted radioisotopes.RayzeBiois alsofunneling cash intoexpandingits HQ in San Diego with plans to further develop internal R&D.

SciNeuroPharmaceuticals

Cornering the untapped Chinese CNS market,SciNeurolaunched with$100 millionin their pocket. Headquartered in Shanghai, the company will also have a hub in Philadelphia.CEO and founder Min Li knows a thing or two from his time running GSKs neuro R&D group before the company shuttered the program in 2017.Li stated, One in every six people in China is living with a CNS condition, yet there are relatively few effective treatments available today, underscoring the urgent need to develop and deliver novel, effective therapies. The impact of CNS diseases extends beyond patientsto their families and society as well. Theassumption isSciNeurowill start with Parkinsons diseaseand painin addition to rare genetic diseases, after scaling up staffing.

BioAge

Looking to extend the humanhealthspan,BioAgeraised$90 millionin an oversubscribed Series C. The companyis at the forefront of understanding the biological drivers of aging with its unique and cutting-edge systems biology platform. A supporting pipeline has medicines to target these key pathways to reverse or eradicate disease and extend the years of healthy life remaining.BioAgeis on the cusp of takingpilot therapies BGE-117 and BGE-175 into clinical trials, targetingthe first half of 2021.According to a press release, proceeds from the financing will be used to build and develop a diversified portfolio of therapies that increasehealthspanand lifespan, augmentBioAgesartificial intelligence (AI)-driven approach to map the molecular pathways that impact human longevity, and further expand capabilities to test drug candidates in predictive models of human diseases of aging.

Remix Therapeutics

Laying down a new track for RNA processing, Remix launched with$81 millionin financing. Funds will be used to support development of theREMastertechnology platform and advance the companys pipeline of RNA processing targeted therapeutics as well.As we reach the limits of what is easily druggable with protein targeting therapies, reprogramming RNA processing represents an exciting new therapeutic opportunity. We believe we can precisely target the cellular complexes that process RNA to address the underlying drivers of disease, working upstream of protein expression, said Pete Smith, Ph.D., co-founder, president and CSO of Remix Therapeutics and Atlas Venture Entrepreneur in Residence.

Pear Therapeutics

Pear picked a sweet dealthis weekwith an$80 millionseries D backed by Temasek, 5am Ventures, Novartis andquite a fewmore.Combining biology and technology, the company specializes in Prescription Digital Therapeutics (PDTs),a new therapeutic class that treats serious disease alone or with drugs using software. PearsreSET,reSET-OandSomrystare the first PDTs to receive FDA approval for treating disease. The products are used to treat substanceuse disorder,opioid use disordersand chronic insomnia, respectively. Series D funds will be used to acceleratereimbursementcoveragefor its three commercial products.

Noema Pharma

Co-founded by the former VP of neuroscience for Roche, Noema Pharma raised$59 millionin a Series A round. With an intent to develop treatment for rare neurological disease whereexisting therapies have not shown much success, the company has licensed four clinical stage assets from Roche. The Roche-assets are aimed at seizures in tuberous sclerosis complex (TSC), trigeminal neuralgia, Tourettesyndrome and other rare neurologicaldisorders.Already having been in clinical studies at Roche, all four candidates have strong clinical and preclinical safety packages. Thisshouldallow Noemato quickly pursue a series of clinical programs in orphan central nervous system (CNS) indications.

Most read today on BioSpace:

View post:
Biopharma Money on the Move: December 2 - 8 - BioSpace

Proceeds will support advancement of the companys pipeline and proprietary platform for identifying and developing therapies to treat diseases of aging

Company announces Chief Medical Officer as it prepares to enter clinic in 2021 with lead Phase 2-ready therapeutic compounds

RICHMOND, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- BioAge Labs, Inc., a biotechnology company developing medicines to treat aging and aging-related diseases, today announced that it has raised $90 million in an oversubscribed Series C financing. The raise was co-led by Andreessen Horowitz and serial entrepreneur, Elad Gil, and included new investors Kaiser Foundation Hospitals, AARP Foundation (through the RockCreek Impact Fund) and Phi-X Capital, the fund of genomics entrepreneur Mostafa Ronaghi, among others. Current investors including Caffeinated Capital, Redpoint Ventures, PEAR Ventures, AME Cloud Ventures, Felicis Ventures, and others also participated.

These additional funds will support advancement of our systems biology and data-driven platform to map the key pathways that drive human aging and our pipeline of medicines that target these pathways to reverse or eradicate diseases and extend healthspan, said Kristen Fortney, PhD, co-founder and chief executive officer. We look forward to advancing our first platform-derived therapies, BGE-117 and BGE-175 into clinical trials in the first half of 2021.

BioAge is at the forefront of understanding scientific drivers of aging with its unique and cutting-edge systems biology platform. We believe their approach has the potential to unlock the underlying pathologies of many diseases, such as Alzheimers, cardiovascular disease, and frailty, that disproportionately affect older populations, said Vijay Pande, PhD, general partner at Andreessen Horowitz.

Drugs that target aging have potential to treat several morbid diseases and improve the lives of older adults. BioAge has built a proprietary engine to analyze molecular signatures in aging populations, and to advance data-driven hypotheses to identify existing clinical-stage drugs that are ready for Phase 2 efficacy trials in age-related diseases. Im excited to work with them as they scale their platform and develop multiple therapies to improve the health of older individuals, said Elad Gil, PhD, entrepreneur and investor.

Proceeds from the financing will be used to build and develop a diversified portfolio of therapies that increase healthspan and lifespan, augment BioAges artificial intelligence (AI)-driven approach to map the molecular pathways that impact human longevity, and further expand capabilities to test drug candidates in predictive models of human diseases of aging.

Separately, the company announced that Paul Rubin, M.D. will lead its clinical development efforts as chief medical officer. Dr. Rubin, a veteran biopharmaceutical drug developer, brings extensive experience from early discovery, late stage development and ultimate drug approvals across a wide variety of therapeutic areas in global geographies. In former roles heading development at Sepracor, GSK and Abbott, Dr. Rubin has been responsible for the clinical development and approval of more than ten products. Prior to BioAge, he was most recently executive vice president, Research and Development for MiRagen and held a similar role at Xoma, two biotechnology companies. Dr. Rubin earned his M.D. at Rush Medical College, Chicago.

Dr. Rubin commented, I am thrilled to be leading the BioAge clinical development team at this exciting time. Our platform provides a unique opportunity to identify targets relevant to the aging process and diseases associated with this process. Diseases common to older patients are often ignored despite their direct association with morbidity, mortality and decreased quality of life. The first two drugs from our pipeline are ready to begin Phase 2 trials in indications targeting serious conditions in elderly populations that presently have no good therapeutic options. A key aspect of our strategy is to initiate efficient human clinical trials that will demonstrate that our drugs can address age-related deficiencies in acute conditions, which may expedite approval and serve as a gateway to the treatment of chronic diseases, resulting in healthy aging.

About the BioAge Platform

The BioAge platform identifies key drug targets that will impact aging. The companys proprietary human aging cohorts have blood samples collected up to 45 years ago, with participant -omics data that is tied to extensive medical follow-up records including detailed future healthspan, lifespan and disease outcomes. BioAge has built a systems biology and AI platform that leverages these rich datasets to identify the molecular drivers of age-related pathology. BioAges pipeline of therapies targeting these key pathways will address the significant unmet medical needs of an aging population.

About BioAge

BioAge is a privately-held biotechnology company developing proprietary drugs to treat aging and aging- related diseases. Since its founding in 2015, the Company has raised $127 million in venture capital funding to back its AI-driven approach to map the molecular pathways that impact human longevity. BioAges mission is to develop a pipeline of therapeutic assets that increase healthspan and lifespan. For additional information about BioAge, visit the companys website at http://www.bioagelabs.com.

Source: BioAge Labs, Inc.

Contact Information:

BioAge | peng@bioagelabs.com

Media | swheeler@wheelhouselsa.com

Read more from the original source:
BioAge Raises $90M to Treat Aging and Age-related Diseases - GlobeNewswire

Wilmington, November, 2020: Axiom Market Research & Consulting added a report on global Stem Cell which includes study on various market segments across various countries of key regions across the globe. Post COVID-19 pandemic impressive growth anticipated for this market. The global market is estimated and forecasted in terms of revenue (USD Million) generated by the Stem Cell market.

Get Sample PDF Copy @ https://www.axiommrc.com/rqs/1661-stem-cell-market-report

Major Players in Stem Cell Market

Some of the key participants in the stem cells market include Cytori Therapeutics, Inc., Mesoblast Ltd., Astellas Pharma Inc., STEMCELL Technologies Inc., Osiris Therapeutics Inc, Celgene Corporation, BioTime, Inc., Cynata Therapeutics Limited, Human Longevity Inc, Cellular Engineering Technologies Inc., U.S. Stem Cell, Inc. BrainStorm Cell Therapeutics Inc. Caladrius Biosciences, Inc., and Promethera Biosciences.

Covid-19 Impact Analysis on Stem Cell Market

The global pandemic of Coronavirus (COVID-19) has triggered stock market unpredictability, tight border controls, and worldwide lockdown, leading the biotechnology industry, as well as large companies and governments, to restock supply chains. The whole world is experiencing severe impact on social and financial sectors, and all global industries are facing challenges during the COVID-19 pandemic. The exclusive COVID-19 Impact Analysis report by Axiom MRC explores the outbreak of COVID-19, its impact on the global and regional economies, and its implications on the healthcare sector. The report studies the effect of the pandemic on the global economy by evaluating factors like consumption, GDP, business investment, key players marketing strategies, key supply and demand-side factors, epidemiological swing factors, inventory, and governmental policies & decisions.

Stem Cell Market Segmental Highlights

Axiom has better understanding of various market segments due to its in-depth value chain analysis. Market size and forecast for the major market segments in terms of value and volume for the forecast period 2019 to 2027 presented in the report

Purchase This Report @ https://www.axiommrc.com/buy_now/1661-stem-cell-market-report

Stem Cell Market Regional Analysis

This study includes market size, share trend, competitive intelligence of developed markets, growth markets and niche regions/countries of:

Research objectives and key highlights of the market study:-

About us:

Axiom Market Research & Consulting is leading market research, business consulting and data analytics company serving the Fortune 5000 companies organizations of Healthcare, Chemicals, Food and Beverage, Technology etc. with quality solutions.

Contact us:

Call: USA +1(845)875-9786/UK +44(0)20 3286 9707/India +91 7020 342806

Email: [emailprotected]

Read this article:
Stem Cell Market Analysis By Industry Value, Market Size, Top Companies And Growth Forecast To 2027 - Cheshire Media

As we look forward to 2021, many of us have started to think about New Year's resolutions. For those of us looking to lose weight over the next twelve months, a brand new diet can not only help us hit our weight loss goals, but also introduces us to new foods, raises our energy levels, and helps us live longer, more fulfilled lives. And yet, if you decide to embark on a brand new diet, figuring out which plan to follow can feel mind-boggling. Trying to sort between the best diets to live longer and the not-so-great fad diets only makes losing weight that much harder.

So if you feel overwhelmed by the world of dieting and have no idea of where to start, have no fear! To help streamline your weight loss process and guarantee a long and healthy life, we talked to a wide range of registered dietitians, nutritionists, and medical doctors to assemble the top six diets that help you live longer. By eating healthy and exercising regularly, you can stay one step ahead of weight gain and keep moving for decades to come.

Read on to learn which six diets can help you live longer, and for even more healthy tips, be sure to check out our list of The 7 Healthiest Foods to Eat Right Now.

"The Mediterranean diet has consistently been ranked by US News & World Report as the world's best overall diet," says Lexi Endicott, RD, LD, and culinary nutrition specialist for To Taste. "Rather than a diet in the traditional sense in which you go on it to eventually go off it, the Mediterranean Diet is a simple and sustainable eating pattern that can be followed for life. This eating pattern emphasizes consuming a variety of plant foodsa plant-forward diet, so to speak."

If you feel ready to take the plunge, the nutritional benefits of this eating plan can keep you healthy for years.

"These healthful foods [and] ingredients are rich in vitamins, minerals, and phytochemicals (i.e. antioxidants) that decrease risk of developing many chronic diseases such as heart disease, cancer, diabetes, and Alzheimer's," says Endicott. "The more disease-free years someone can add to their life, the better!"

If you want to really super boost your chances for longevity, check out our list of 20 Foods You Should Be Eating Every Day for a Longer Life.

Eating less can definitely help you lose weight, but it might also keep you around much longer.

"The diet that has the most empirical evidence in regards to increasing life expectancy is intermittent fasting or even fasting in general," says Dr. Alexander Lightstone Borsand, MD. "Animal studies have shown that the less often animals eat, the longer they live in comparison to animals fed more regularly. The most notable study in humans followed 2,000 patients after cardiac catheterization and showed an increased lifespan in patients who regularly fasted."

"Another animal study showed that mice that were fed once a day had an 11% increase in lifespan as compared to the mice fed multiple times a day," says Dr. Borsand. "This is a significant increase in lifespan and warrants further human studies."

Here are7 Science-Backed Benefits of Intermittent Fasting.

If you haven't heard of the DASH diet, get ready for an eating plan that can change your life. The Dietary Approaches to Stop Hypertension diet encourages the consumption of foods that lower blood pressure has taken off in recent years, and can do some wonders.

"The science is very clear that a plant-based or plant-forward diet is quite remarkable for its positive impact on longevity and healthspan," says Dr. Nicole Harkin, MD, FACC, founder and cardiologist of Whole Heart Cardiology. "This diet is high in vegetables, fruits, whole grains, legumes/beans, nuts, and seeds while minimizing or eliminating animal products and processed packaged foods."

"Numerous epidemiologic studieshave demonstrated that an increased intake of plant-based foods results in reduced risk of cardiovascular and other causes of death," says Dr. Harkin. "We also see a decreased risk of obesity, high blood pressure, high cholesterol, diabetes, and inflammation. While not all individuals may not be ready to go completely plant-based, working on incorporating as many plant-based foods and #meatlessmondays is a great first step!"

Here is Everything You Need to Know About the DASH Diet.

What do Greece, Japan, Italy, California, and Costa Rica have in common? These areas constitute Blue Zonesareas of the world with the highest concentration of centenarians. In order to live like someone who could reach 100, you need to eat like someone who can reach 100, and this diet helps you do just that!

"The Blue Zones have several lifestyle factors in common which appear to contribute to the longevity and increased likelihood of living to 100 years of age," says Dr. Christine Bishara, MD, founder of From Within Medical. "Their diets are composed of fresh whole foods which are primarily plant-based and also include nuts, legumes, and olive oil. They incorporate minimal red meat with the majority of the animal protein components coming from pescetarian options."

They do not eat heavy meals late in the day or close to bedtime," says Dr. Bishara. "They practice socially based eating and have strong ties to their community. This has been studied numerous times as a major factor in longevity including another study called 'The Roseto Effect'[ and] they live in areas with ease of daily walking as a form of exercise. This seems to also be another well-studied contributor to longevity."

People in the blue zone typically eat this One Food You Should Be Eating Every Day For a Longer Life.

"Though it sounds like the latest trend, the carnivore diet is a diet that was followed for ages," Dr. Rashmi Byakod said. "The human race evolved from eating raw and cooked meat. In the olden days, there was no agriculture, and plant food was the least consumed. Meat foods are highly nutritious and carry numerous health benefits."

If you ever considered yourself a "meatatarian" you might actually be onto something.

"The aging process indicates impairment of mitochondrial function, reduced antioxidant effect, and increased oxidative stress," says Dr. Byakod. "Selenium and Coenzyme Q10 (CoQ10) present in meats have antioxidant effects helping in longevity and wellbeingOther than these, meats are a good source of vitamin D, omega 3 amino acids, and various other nutrients. Adapting to a carnivore diet can help you meet all the nutritional requirements of your body."

If you love the idea of the Mediterranean diet, but don't want to cut our dairy, this diet will make you swoon.

"Dairy, especially full-fat dairy, contains healthy fats, calcium, and other nutrients that are recommended for a healthy diet," says Lisa Richards, CNC. "It is easy to integrate more servings of dairy into the traditional Mediterranean diet through cheeses, yogurt, and dairy-based sauces."

"Adding dairy to the Mediterranean Diet could make it more sustainable long-term, especially for women who need the added calcium and vitamin D," says Richards. "The fat content may deter some people as it adds additional fat to an already moderate fat diet, however, easy exchanges can be made to ensure a balance of fish and plant fat with added dairy."

"As with any diet, moderation is important," says Richards. "The foods recommended on the Mediterranean Diet are not shown to be unhealthy for your heart. However, the dieter should make sure they are still staying within their calorie limits, especially with fat content, to avoid any negative side effects."

For more on the Candida Diet: This Is Everything You Should Eat and Why, According to Experts.

Continued here:
The 6 Best Diets That Will Make You Live Longer, Say Dietitians - Eat This, Not That

The rapid adoption of telemedicine and digital health during COVID-19 pandemic is remarkable, yet unsurprising. In the years preceding the health crisis we now find ourselves in, a paradigm shift in health care toward digitization was percolating. Structural trends like health care inequality, human longevity, systemic inefficiency, and improving connectivity served as kindling for the seemingly inevitable, albeit gradual adoption of technology in the sector.

2020's global lockdowns and widespread infection fears ignited said kindling. Since March, we've witnessed levels of technological disruption typical of years, not mere months. FAIR Health reports telemedicine claim lines increased about 84x from April 2019 to April 2020.1 Artificial intelligence (A.I.)-equipped health care analytics software became a valuable tool for drug and vaccine development, symptom identification, and hospital triaging.2 Connected devices like health tracking wearables and smart thermometers became commonplace, while those found in remote intensive care units allowed doctors to treat patients without risking their own health. In other words, telemedicine and digital health arrived.

In the following piece, we explore four key companies at the center of this rapidly emerging theme.

Teladoc Health (NYSE:TDOC) is a telemedicine company that connects patients with health care providers over the phone, through video chat, and on the Teladoc platform. Teladoc's primary services include:

Usage of Teladoc's platform has surged through the pandemic as patients seek medical care without risking infection from in-person visits. In Q2 2020, during pandemic's initial surge, Teladoc provided 2.8 million virtual health care visits, up 200% year-over-year (YoY).6 Many expected visits to decrease as COVID-19 infections subsided over the summer, but Q3 usage levels remained steady with Teladoc yet again recording another 2.8 million.7 As of the end of Q3, Teladoc had 51.5 million members, up 47% YoY. Also of note, in October, Teladoc completed its acquisition of remote health monitoring company, Livongo (NASDAQ:LVGO), for $18.5B in cash and stock. The deal integrates Livongo's established remote monitoring technology with Teladoc's telemedicine infrastructure, broadening and possibly solidifying Teladoc's standing as a leader in virtual care.8

Nuance Communications (NASDAQ:NUAN) offers a suite of products that enable digital transformation in health care, spanning the health care analytics and administrative digitization segments. These include:

Nuance's health care analytics and administrative digitization products continued to show strength throughout the pandemic. In Q4 of their 2020 fiscal year, Nuance reported continued growth for Dragon Medical One (DMO), with penetration in the US reaching 43% and with segment revenues growing 26% YoY. The product is growing internationally, too, reaching 14 countries and showing notable strength in the United Kingdom. DMO's strength comes in tandem with increased adoption of Nuance's cloud-based health care platform, with both products benefitting from shared synergies and the general trend of digitization.

iRhythm Technologies (NASDAQ:IRTC) develops and sells solutions for monitoring cardiac health and detecting cardiac arrhythmias. Their products include:

In Q2 2020, in the midst of the pandemic, iRhythm's leadership noted how the current environment offers "considerable potential for structural changes to how healthcare is delivered, and that will play to the strengths of [their] digital platform."14 Q3 validated this sentiment with a significant number of clients prescribing Zio at a higher clip than at the beginning of the year, despite the pandemic easing during the quarter. Additionally, the rise of telemedicine drove greater enrollments on the Zio platform, illustrating how the theme's sub-segments are both enablers and beneficiaries of each other.

Invitae Corporation (NYSE:NVTA) provides patients and providers with germline genetic testing and offers libraries of genetic data for health care provider implementation. Invitae's data provides insights around the risk of developing cancer and other diseases based on mutations found in cellular DNA. This can be extremely useful for patients looking to proactively understand their health risks and for providers looking to offer their patients the best care available.

Genetic data has become increasingly valuable during the pandemic as it is becoming apparent that certain genetic risks increase the lethality of COVID-19. Invitae's Q3 2020 results reflect these developments as testing volumes grew 32% YoY and 41% compared to the previous quarter. Additionally, Invitae closed on a $1.4B deal to acquire Archer DX, increasing their offering to include somatic testing which looks at genetic changes seen in tumors. The potential market for genetic testing is vast, and companies like Invitae are making this technology and information more readily available to patients around the world.15

Despite impressive advancements in recording and analyzing health care data and in connected medical devices, the healthcare sector was slow to embrace the digital transformation offered by these technologies for many years. The COVID-19 pandemic finally put this disruption in motion. As illustrated by the compelling products and services mentioned above, solutions that enable remote medicine, advanced patient monitoring, A.I.-driven insights, and streamlined healthcare administration are rapidly being implemented around the world. In our view, the benefits seen by patients, providers, and payers will continue to drive the theme's growth moving forward.

FOOTNOTES

1. Fair Health, "Telehealth Claim Lines Increase 8,336 Percent Nationally from April 2019 to April 2020," July 7, 2020.

2. The Medical Futurist, "The (Sober) State of Artificial Intelligence in the Fight Against COVID-19," April 14, 2020.

3. Teladoc, "Virtual Primary Care," 2020.

4. Teladoc, "What We Do," 2020.

5. Ibid.

6. Teladoc Q2 Earnings Call

7. Teladoc Q3 Earnings Call

8. Med City News, "Teladoc, Livongo finalize $18.5B merger," Oct 30, 2020.

9. Nuance Communications, "Provider Solutions," 2020.

10. Ibid.

11. Ibid.

12. iRhythm, "Zio XT," 2020.

13. iRhythm, "The Zio Service," 2020.

14. iRhythm Q2 Earnings Call

15. Invitae Q3 Earnings Call

Investing involves risk, including the possible loss of principal. The investable universe of companies in which EDOC may invest may be limited. The Fund invests in securities of companies engaged in the Health Care and Information Technology sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. EDOC is non-diversified.

This information contains a manager's opinion, is not intended to be individual or personalized investment or tax advice, and should not be used for trading purposes.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns.

Carefully consider the funds' investment objectives, risks, and charges and expenses. This and other information can be found in the funds' full or summary prospectuses, which may be obtained at globalxetfs.com. Please read the prospectus carefully before investing.

Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC.

Original Post

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.

Read more from the original source:
4 Companies At The Center Of The Telemedicine And Digital Health Revolution - Seeking Alpha

Zach Bush MD, is an internationally recognized educator and thought leader on the microbiome as it relates to health, disease, and food systems. Celebrating World Microbiome Day on 27th June 2021, he explained why theres no better time to pay tribute to the microbiome.

As human beings, our neurologic capacity begins with our connection to the microbiome Zach Bush MD

In his latest weekly newsletter, Bush said, It is, in its entirety, vital to life and the reason why we are here today. Without the microbiome, life on Earth would not exist.

At its most basic definition, micro means small, and biome means living creatures essentially all of the living microbes on and inside the human body. Today, we know human cells are not at the foundation of the human microbiome, but rather its the fungi and bacteria that are. It is estimated that we have 50 to 70 trillion human cells, which pale in comparison to the 1.4 quadrillion bacteria and 10 quadrillion fungi inside our bodies.

He explained further that as we learn more about the microbiome and our human biology, its clear that this diverse non-human micro ecosystem is what makes life possible. Its what fuels our development, immunity, and nutrition, enabling our production of energy, micronutrients, and regenerative pathways. Within every organ system throughout our whole body, its this unique niche of bacteria, fungi, and yeast that nurture our human cells.

Get out! Kick off the shoes, walk in a garden, on a forest path, a beach, a meadow, or a mountain top. Zach Bush, MD

World Microbiome Day was celebrated on the 27th June. You can read more about it here: #microbiome4life

Zach Bush MD is a physician specializing in internal medicine, endocrinology and hospice care. He is an internationally recognized educator and thought leader on the microbiome as it relates to health, disease, and food systems. Dr Zach founded *Seraphic Group and the nonprofit Farmers Footprint to develop root-cause solutions for human and ecological health. His passion for education reaches across many disciplines, including topics such as the role of soil and water ecosystems in human genomics, immunity, and gut/brain health. His education has highlighted the need for a radical departure from chemical farming and pharmacy, and his ongoing efforts are providing a path for consumers, farmers, and mega-industries to work together for a healthy future for people and planet.

Link:
Quote Of The Week: Zach Bush MD On World Microbiome Day - Longevity LIVE - Longevity LIVE

Posted on Dec 27, 2020 in Science

Planet Earth Report provides descriptive links to headline news by leading science journalists about the extraordinary discoveries, technology, people, and events changing our knowledge of Planet Earth and the future of the human species.

Ghostly Circles in Space Cant be Explained by Current Theories Among them was a picture of a strange circle of radio emission, hanging out in space like a cosmic smoke-ring reports astronomer Ray Norris for The Conversation. None of us had ever seen anything like it before, and we had no idea what it was, report scientists examining new images from pilot observations for the Evolutionary Map of the Universe (EMU) project, made with CSIROs revolutionary new Australian Square Kilometer Array Pathfinder (ASKAP) telescope.

How a Software Map of the Entire Planet Could Change the World Forever, reports Aaron Frank for the Oxford Business Review. Why 3D map data is the technology infrastructure for the 21st Century 3D maps like these are essentially software copies of the real world. They will be crucial to the development of a wide range of emerging technologies including autonomous driving, drone delivery, robotics, and a fast-approaching future filled with augmented reality.

The Darkest Timeline Deep Adaptation made people confront the end of the world from climate change. Does it matter if its not correct? asks Jonah Engel Bromwich for the New York Times.

The Mysterious Link Between COVID-19 and Sleep, reports James Hamblin for The Atlantic. The coronavirus can cause insomnia and long-term changes in our nervous systems. But sleep could also be a key to ending the pandemic.

From Elvis worms to the Milky Ways edge, these science stories sparked joy in 2020, reports Science News. From Flowers at the South Pole to microbes that had been buried in seafloor sediments for more than 100 million years revived and multiplied.

How scientists plan to protect Earth from extraterrestrial germs, reports Rebecca Renner for National Geographic. As missions return more cosmic material, cautious space agencies are building highly secure biosafety labs to keep the precious cargo contained.

The shadowy spirits that helped advance science A demon was present at the birth of science.. Ren Descartes conjured an evil genius when devising his I think, therefore I am statement about the nature of reality and the self. Other scientific demons would follow over the centuries, reports Jess Keiser for The Washington Post. Descartes realized that in order to establish anything at all in the sciences that was stable and likely to last, he first needed to lash himself to a single point of certainty in a roiling sea of doubt.

Wild Things Space Invaders Season 2: The Search for Extraterrestrial Life (Best Space Podcast of 2020) Whats the likelihood that, as were looking out into space, something else might be looking back at us? asks Host Laura Krantz. in recent years, armed with state-of-the-art technology and better information, the search for extraterrestrials overflows with exciting possibilities. Within our own solar system, astrobiologists search for the biochemical building blocks that might sustain microbes. Astronomers discover far-flung stars, orbited by planets that could be teeming with life. And astrophysicists point sophisticated (and expensive) telescopes toward the deep reaches of the universe, looking for anything out of the ordinary.

Zombie Gas Could Creep Through Arctic Ice, reports Elizabeth Rayne for SyFy Wire. Melting permafrost has revealed everything from Scythian graves to unbelievably intact Ice Age megafauna, but something else that has been lurking under frozen ground that was never supposed to melt. New research has now found that zombie greenhouse gases could seep through melting Arctic permafrost because of human activity that is causing it to melt and the organic matter in it to decompose. Carbon dioxide and methane had been trapped in undersea permafrost since mammoths and woolly rhinos roamed the Earthand are now reanimating.

The Secret to a Long, Healthy Life Is in the Genes of the Oldest Humans Alive, reports Shelly Fan for Singularity Hub. The key to human longevity, [a global team of scientists] say, lies in the genes of centenarians. These individuals not only live over 100 years, they also rarely suffer from common age-related diseases. That is, theyre healthy up to their last minute. If evolution was a scientist, then centenarians, and the rest of us, are two experimental groups in action. Nature has already given us a genetic blueprint for healthy longevity. We just need to decode it.

Monkey Brain Study Reveals the Engine of Consciousness, reports Grace Browne for Inverse. What exactly ignites consciousness has long been a mystery. But in a study published in February, the search became a bit narrower: to a powerful part of the brain known as the central lateral thalamus, a tiny region found deep in our forebrain.

The Worlds Space Agencies Are on a Quest to Deflect a (Harmless) Asteroid, reports Jason Dorrier for Singularity Hub. While the last killer space rock dropped out of the sky with no warning, we have a few tools the dinosaurs didnt. In addition to telescopes to chart potentially hazardous asteroids, we can visit and, theoretically, divert an asteroids course before it reaches us. Now, the worlds space agencies are teaming up to take planetary defense beyond theory.

Extraterrestrial evidence: 10 incredible findings about extraterrestrial life from 2020, reports Adam Mann for Live Science. Findings on the closest planet to us, in the outer solar system and the far beyond seemed to point to the possibility that other worlds could host organisms ranging from bacteria to technological beings. Perhaps, new results in the coming year will finally reveal who else might be out there.

2020 in review: The year governments slapped down big tech This was a year in which governments went head-to-head with big tech firms. US regulators were suing Facebook over its historic acquisitions of Instagram and WhatsApp, asking the courts to consider breaking up the company, reports New Scientist.

After Coronavirus the World Will Never Be the Same. But Maybe, It Can Be Better, reports Vanessa Bates Ramirez for Singularity Hub. Were making plans for what well do when things go back to normaland banking on that happening. But what if life never fully goes back to how it was pre-coronavirus? What if this epidemic is a turning point, and after it the world is never the same? More importantlyor, at least, more optimisticallywhat if the world could come out of this crisis better than it was before?

Rumors of a murder hornet apocalypse may have been exaggerated, reports Murder hornets sightings in the Pacific northwest inspired a mix of concern and delight, reports Science News.

The Wildest Animal News From 2020 These are the stories about birds, bugs, fish and mammals that surprised and delighted readers the most this year, reports Hannah Wise and Lily Benson for The New York Times. It was a rough year for Homo sapiens. The coronavirus pandemic highlighted our vulnerabilities in a natural world that is constantly changing. Many were pushed to find new levels of resolve and creativity to survive.

Here is the original post:
Planet Earth Report Strange Unexplained Circles in Space to Software Map That Could Change the World Forever - The Daily Galaxy --Great Discoveries...

UK and Russian scientists are to test whether combining shots of the Oxford/AstraZeneca and Sputnik V coronavirus vaccines could result in better protection than two doses of the same one.

Trials will start by the end of the year, the Russian Direct Investment Fund (RDIF), which funded the development of the Sputnik V vaccine by Russias Gamaleya Institute, said on Friday. AstraZeneca confirmed that it was considering how it could assess combinations of different vaccines, and would soon begin exploring with the Gamaleya Institute whether their two vaccines could be successfully combined.

Like the Oxford/AstraZeneca vaccine, the Russian Sputnik V shot is based on a modified version of adenovirus, a common cold virus. This vector is stripped of any disease-causing genes and modified to carry genetic instructions for making the coronavirus spike protein, which it passes to human cells. The manufactured coronavirus spike protein then triggers an immune response that protects against the Covid-19 disease.

A potential problem with such vaccines, however, is that of anti-vector immunity, where if the immune system has previously encountered the type of adenovirus used in the vaccine, it may destroy it before the vaccine can trigger an immune response. This is why the Oxford University group chose to use a chimp adenovirus, rather than a human one. However, anti-vector immunity could also reduce the efficacy of booster shots, if this involves injecting the same virus for a second or third time.

Mixing and matching different vaccines may provide a solution. This concept is known as a heterologous prime-boost, and has been used in vaccination programmes against other diseases.

Now that the UK has authorised the first Covid vaccine, who will get it first?

The governments Joint Committee on Vaccination and Immunisation (JCVI) says its priority is to prevent Covid-related deaths and protect health and social care staff and systems.

Elderly care home residents and their carers are first on the JCVIs list because their risk of exposure to the virus is higher and because the risk of death closely correlates with older age. They are followed in priority by anyone else over 80 and frontline health and social care workers.

Even so, for pragmatic reasons NHS staff are likely to be the first group to receive the Pfizer/BioNTech jab. This is because the vaccine needs to be stored at ultra-cold temperatures, which can be achieved more easily by using hospital facilities

Are there enough doses to reach all the priority groups?

Together, care home residents, their carers and the over-80s make up nearly 6 million people, and frontline NHS staff a further 736,685. Matt Hancock, the health secretary, has said he expects 10m doses of the Pfizer/BioNTech vaccine to be available this year, so if this is the only vaccine authorised, everyone else would have to wait until further doses become available next year.

Where will I go for the vaccine?

Covid-19 vaccines are expected to be delivered at three types of venue: NHS trust vaccine hubs at hospital sites; mass vaccination centres, which are in the process of being set up at places such asfootball stadiums, conference buildingsand racecourses these are expected to vaccinate up to 5,000 people a day; and at GP surgeries and pharmacies. GPs can also visit care home residents and housebound patients at home without them needing to travel.

How far apart will the two doses be administered, and will I protected after the first?

While there is some evidence to indicate high levels of short-term protection from a single dose of vaccine, a two-dose schedule is what has been approved by theMHRA.

The second dose will need to be delivered at least 21 days after the first, and both will be injected into the deltoid muscle the thick triangular muscle we use to raise each arm.

For the Pfizer vaccine, its efficacy rate was calculated seven days after the second shot. It is likely that people will have some protection before this, but this is how long it will take for full protection to kick in. We will learn more about the extent of protection and how long it lasts as data from ongoing clinical trials comes in.

Can I pay to get the vaccine privately?

Unlikely. Englands deputy chief medical officer, Jonathan Van-Tam, has said he believes Covid-19 vaccines should be delivered according to clinical priority rather than allowing people to jump the queue if they can afford it.

Will I be able to choose which vaccine I have?

Also unlikely, at least in the short to medium term. Assuming more than one vaccine is approved, the priority will be distributing any available doses to the people who need it as quickly as possible.

Linda Geddes

Unlike AstraZenecas vaccine, Sputnik V uses two different human adenovirus vectors to try to trigger a stronger and longer-term immune response. It is not yet clear which of these components will be tested alongside the AstraZeneca vaccine.

Anti-vector immunity could also provide a possible explanation of why the AstraZeneca vaccine appears to work better when given as a half-dose followed by a full one, rather than two full doses.

Earlier this week, the outgoing chair of the UKs vaccine taskforce, Kate Bingham, announced that a trial of AstraZenecas vaccine in combination with the Pfizer shot was likely to begin in January. Its to do with trying to trigger the immune response and the durability [of the response], she said.

RDIF said it approached AstraZeneca about the possibility of combining its vaccines on 23 November.

This could eventually extend the duration of immunity and possibly also protect against people receiving the same vector repeatedly and having a less robust response, said Beate Kampmann, the director of the vaccine centre at the London School of Hygiene & Tropical Medicine. But for now these are all theoretical concepts that need to be carefully tested before they can be extended to population use.

Russia is likely to see the move as a vote of confidence by a western manufacturer in Sputnik V, which is already being used to immunise medical workers, teachers and social workers. Russian officials previously announced that the vaccine had more than 95% efficacy, giving it a success rate comparable to vaccines being developed by Pfizer and Moderna.

The decision by AstraZeneca to carry out clinical trials using one of two vectors of Sputnik V in order to increase its own vaccines efficacy is an important step towards uniting efforts in the fight against the pandemic, said Kirill Dmitriev, chief executive of RDIF. We hope that other vaccine producers will follow our example.

Dr Stephen Griffin, associate professor in the school of medicine, University of Leeds, said: The importance of a second jab should not be underestimated as it is important for the longevity, specificity and effectiveness of the response to most vaccines.

Visit link:
Oxford Covid vaccine to be combined with Sputnik jab for trial - The Guardian

Contrive Datum Insights Pvt. Ltd. has recently announced a new statistical data, titled as Genomic Biomarker Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2027.

It includes the research studies about the current trends in different sectors on the basis of their scope. The analyst of this report focuses on the static and dynamic pillars of the industries, for basic understanding of the strategies. In addition to this, it identifies the drivers and opportunities for the development of the businesses. Additionally, it focuses on restraints to analyze the issues from the existing business strategies. It focuses on the various aspects, such as application areas, platforms, and leading players operating across the globe.

Top Key Players:

Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher Scientific, Roche, QIAGEN, Epigenomics, Almac, Pfizer, Human Longevity, ValiRx, Personalis, Eagle Genomics, Empire Genomics, Agilent, Illumina.

In addition to this, the top manufacturers are based across different regions such as, Japan, China, Asia, Europe, and India. The study explains the facts and figures about the production, price, and revenue of the Genomic Biomarker market. To give clear understanding of global Genomic Biomarker market, several questions have been addressed on the basis of the industries.

Free Sample Report + All Related Graphs & Charts (Including COVID19 Impact Analysis) @: https://www.contrivedatuminsights.com/request-sample/22053

Different market assessment techniques are studied to audit the market. The report has been highlighted on the basis of historical data, current statistics, and future predictions. Along with this, the financial overview and recent developments are explained effectively to give better insights for the growth of the businesses.

It summarizes the detailed information of the market segments based on different terms, such as strategy, scope, and manufacturing base. The sellers as well as the buyers are significant key players in this market and hence, this report has elaborated on the same. In addition to this, the study explains the impacts of the key factors on the domestic as well as global market.

Avail 20% Discount on various license types on immediate purchase @: https://www.contrivedatuminsights.com/request-discount/22053

Global Genomic Biomarker Market Segmentation:

By Type

Oncology, Cardiology, Neurology, Nephrology

By Application

Hospitals, Diagnostic and research laboratories

Points Covered in The Report

Table of Content (TOC):

Chapter 1 Introduction and Overview

Chapter 2 Industry Cost Structure and Economic Impact

Chapter 3 Rising Trends and New Technologies with Major key players

Chapter 4 Global Genomic Biomarker Market Analysis, Trends, Growth Factor

Chapter 5 Genomic Biomarker Market Application and Business with Potential Analysis

Chapter 6 Global Genomic Biomarker Market Segment, Type, Application

Chapter 7 Global Genomic Biomarker Market Analysis (by Application, Type, End User)

Chapter 8 Major Key Vendors Analysis of Genomic Biomarker Market

Chapter 9 Development Trend of Analysis

Chapter 10 Conclusion

Get Research Report within 48 Hours: https://www.contrivedatuminsights.com/buy/22053

Note: This content doesnt contain all the Information of the Report please fill the form (via link) and get all interesting information just one click in PDF with the latest update with chart and Table of Content

Any special requirements about this report, please let us know and we can provide custom report.

About Us:

Contrive Datum Insights Pvt. Ltd. (CDI) is a global delivery partner of market intelligence and consulting services to officials at various sectors such as investment, information technology telecommunication, consumer technology, and manufacturing markets. CDI assists investment communities, business executives and IT professionals to undertake statistics based accurate decisions on technology purchases and advance strong growth tactics to sustain market competitiveness. Comprising of a team size of more than 100 analysts and cumulative market experience of more than 200 years, Contrive Datum Insights guarantees the delivery of industry knowledge combined with global and country level expertise.

Contact us:

Anna Boyd

Contrive Datum insights Pvt. Ltd.

Canada: +19084598372

Website http://www.contrivedatuminsights.com

Read this article:
Genomic Biomarker Market Projected to Witness a Double-Digit CAGR During 2021 2028 | Bio-Rad, Beckman Coulter, Myriad Genetics, Thermo Fisher...

The best way to tackle the worsening climate crisis is to slash emissions of greenhouse gases, which are largely released by burning fossil fuels. At the same time, allowing the natural world to recover from spiralling levels of degradation caused by human activity will draw down and store carbon, while also boosting biodiversity, helping to protect the planet.

Getting on with this two-pronged approach ought to be our species number one priority. But while governments and businesses debate how they go about doing this, there have also been many useful developments in science, technology and in government policy that can support this process, or offer parallel assistance to protecting the environment.

With the impacts of the climate crisis looming large over 2021, The Independent takes a look back at some of the most significant climate developments from this year.

Click on the title of each one to read the full article.

The farming of insects for food has been billed as the next sustainable food revolution in western countries many times over in the past few years. One reason for this is, compared with traditional livestock such as beef and lamb, insects require far fewer resources and produce fewer greenhouse gas emissions.

Ideas for reflecting away more of the suns rays range from painting buildings bright white to sending giant mirrors into space. If they were ever deployed at scale, each of these proposed technologies would come with novel scientific, political and ethical challenges.

Beyond tree-planting, carbon capture technology has not arrived at scale yet, but enormous strides are rapidly being made in the field. It is now possible to put fossil fuels right back where they came from and were safely stored for millions of years, in the interior of the Earth, not flowing and floating around the exterior. In April, The Independents Andy Martin investigated the potential for carbon capture and storage technology to offer a real solution to the climate crisis.

An electric-powered flying taxi, which was demonstrated at a Paris air show earlier this year, will be ready for passengers by the 2024 Olympics in the French capital, its creators said at the time. The VoloCity air taxi looks like a tiny helicopter with two seats and is topped by 18 rotors fixed to a large circle.

The German start-up is working with the French Civil Aviation Authority to bring electric air taxis to the le-de-France region.

Tree planting could play a crucial role in helping European countries adapt to worsening droughts driven by the climate crisis, a study released over the summer found.

The new research suggested that as well as soaking up CO2, planting new forest across agricultural land in Europe would also boost local rainfall levels.

US company Pavement Technology from Cleevland, Ohio, has invented a titanium-based spray which they say acts as a "sunblock" for asphalt roads. The technology acts to scatter radiation from the sun, and also gives roads greater longevity, its creators said.

The UKs heavily degraded peatlands account for around 5 per cent of our total greenhouse gas emissions, but they should be an essential carbon store, not a source. Now, major efforts are underway to bring back this critical resource. A 327-hectare site in Yorkshire is at the forefront of the efforts to restore them to their former boggy glory.

This summer the UK government said it will ban the sale of new petrol and diesel trucks by 2040 as part of plans to slash greenhouse gas emissions.

A ban on the sale of new petrol and diesel cars and vans by 2030 was announced in November 2020 under Boris Johnsons 10-point climate plan.

Free public transport and schemes to help people green their homes were among actions recommended by a major new report which asked citizens how the UK should get to grips with the climate crisis.

Generating entirely renewable clean energy, from which water would be the only waste product, is feasible and scientists are homing in on the exact means of achieving it, according to research published in July.

A team from Trinity College Dublin is fine-tuning a means of using renewable electricity to split water molecules into their constituent atoms, to release energy-rich hydrogen, which they say could be stored and used in fuel cells.

The process is already possible, and can be done using wind or solar power to generate the electricity required to split the water molecules.

Humanity still has the ability to change course and avoid the worst consequences of the climate crisis, scientists said after the UNs latest grim global climate assessment.

In this article The Independent looked at 14 ways individuals can take action.

Food production makes up a third of global greenhouse gas emissions with livestock for beef, lamb, pork and dairy accounting for 14.5 per cent of that. Transforming how we grow food, and what we eat, is a crucial pillar in tackling the climate crisis.

Solutions include: Vertical farms inside supermarkets, using derelict urban sites to grow food close to population centres, and using novel materials such as seaweed for packaging liquids.

The UK government is to spend just over 100m to kickstart a world-leading hydrogen economy, which it hopes will help the fuel become a major energy source and play a significant role in decarbonising heavy industry.

Hydrogen has long been tipped as a clean green fuel that might be used to replace fossil fuels in combustion-based sectors that are more difficult to electrify, such as aviation, shipping, steel and chemical production and other heavy industry.

The worlds first and largest factory to capture and convert carbon dioxide from the air into stone began operations in Iceland in September.

The Orca plant set up by Swiss startup Climeworks AG aims to reduce the effects of the greenhouse gas on the planet and its launch represented a milestone in the direct air capture industry.

Local authorities should not unnecessarily put street lights into rural areas where people could use torches, Lord Deben, the chairman of the Climate Change Committee, said in September.

Light pollution in rural areas has been named as a key reason for the sharp decline in insects across Europe in recent decades, with fears the insect apocalypse could result in a catastrophic collapse of ecosystems across the natural world.

British agriculture could receive a boost worth millions of pounds a year if thousands of honeybee hives were located in solar parks across the country, scientists said in October.

Rising demand for solar power as the UK targets growth in clean energy ahead of its legally-binding 2050 net zero plan, has seen the expansion of large grassy parks covered with solar panels, many of which are situated close to areas of intensive agriculture.

Honey bees living on solar farms could bring major benefits to farmers, researchers say

(Getty)

Speaking in October, the most senior scientific advisor to the UK government, Sir Patrick Vallance, said harnessing the benefits of the natural world is a critical part of hitting net zero by 2050, and must sit alongside innovation in science and technology to tackle the climate crisis.

Sir Patrick warned against relying on magic new technology to solve environmental problems.

This has to be viewed as an all-systems approach, he told The Independent on the role the natural world can play in tackling the climate crisis.

Government scientific advisers from all over the world united in October to call for people to change their personal behaviour in order to help tackle the climate crisis. There will be a move away from the extent of meat-eating weve seen in the past, and I think we all need to think about our flying habits, they said.

Iceland derived 65 per cent of its primary energy from geothermal sources in 2016. Around 85 per cent of all Icelandic homes are heated by geothermal energy. The countrys electricity comes almost exclusively from low-carbon hydropower and geothermal sources.

The UK is not actively volcanic and does not have geothermal reserves on the same scale as Iceland. But there are hotspots across the country with potential for developing geothermal energy. This includes Cornwall, where the countrys first geothermal power plant was commissioned earlier this year.

On the site of the Hellisheidi Power Station, the worlds third-largest geothermal plant located in southwestern Iceland, a world-first experiment has started capturing CO2 straight from air and turning it to stone.

It is a collaboration between Swiss start-up Climeworks, which has created technology to suck CO2 from the atmosphere, and Icelands Carbfix, a company that has developed a technique to turn CO2 to stone in less than two years.

A swathe of Englands biggest land owners and managers signed a joint pact in November, committing them to large-scale habitat restorations and a major tree-planting programme across a portfolio of 10.5 million acres, to help boost biodiversity and tackle the climate crisis.

The organisations, including the National Trust, RSPB and the Duchy of Cornwall have said they will work together to protect and regenerate environments such as peat bogs, woodland and rivers, to help draw down carbon and provide functioning ecosystems in order to help the UKs legally binding goal of reaching net zero by 2050.

This month, the government announced the creation of a new concept aircraft which it says will run on liquid hydrogen and could one day fly to the other side of the world with zero carbon emissions and just one refuelling stop.

The 15m project has put forward a design for a mid-size passenger plane that will be able to accommodate 279 passengers and fly halfway around the globe without needing to refuel, or anywhere in the world with one refuelling stop, the government said.

Australia has been ranked one of the planets worst climate performers in multiple league tables, but now some old coal power stations may be converted to run on hydrogen.

The Liddell and Bayswater power stations in New South Wales Hunter Valley currently account for over 40 per cent of the states carbon dioxide emissions.

More here:
Flying cars and sunblock for roads: The best climate solutions of the year - The Independent

The assurance of longevity comes from this. The people who use our facilities will continue to get the best treatment, stated Kindra Mulch, RN, Director of Administrative Services for KCCHSD.

Were ensuring future generations of Kit Carson County residents have access to health care, added Centura Vice President of Integration Josh Neff.

The union became official in mid-January with a two-year contract amid the hopes of continuing the relationship for many years.

Centura Health is the largest health care network in Colorado and Western Kansas. It is a faith-based nonprofit organization formed in 1996 by Adventist Health System and Catholic Health Initiative. Centura Health has 21,000-plus mission-centered professionals sharing the organizations ministry and mission to extend the healing ministry of Christ by caring for those who are ill and by nurturing the health of the people in its communities.

Among the services Centura will provide is helping to vet and employ a permanent CEO for the KCCHSD. Darcy Howard has been CEO in an interim capacity since mid-summer, but has not expressed an interest in the position permanently. Howard has said she will remain onboard as long as the process takes to bring in her replacement.

Centura will also help and advise in a variety of other capacities, including operations, finance, quality, human resources, patient/safety experience, service line development, and additional health care providers including specialists if necessary, while not stepping on the toes of those providers currently working with the district.

Centura has no intent, nor do we have the capability to make sweeping staff changes, Neff stressed. Centura will consult with the board, but make no decision on staff.

These folks have been in the community a while, established patient care. We want to be careful to point out this is not a Centura-or-nothing situation.

There is no ownership change in this agreement. The KCCHSD Board retains all decision-making authority for the district, and Centura does not share in any financial or operational risk.

Also, Centura will have no say in charges administered by the KCCHSD. Howard acknowledged any price decisions are made with the help of a service named Chargemaster and are entirely separate from this union.

In fact, Neff noted that Centura has been working with Governor Jared Polis task force to reduce medical costs in the state.

We understand the cost of health care is expensive too expensive, Neff stated.

In other words, those receiving services from KCCHSD will continue to get the best treatment available, Howard noted.

KCCHSD has always put our patients and our communities first, and the relationship with Centura will not change that. Our patients will continue to maintain the same high-quality interaction with the hospital and our providers, Howard declared. Centura Health has a number of prestigious awards and honors recognizing their outstanding care, quality outcomes and patient satisfaction. We are confident our relationship will serve to help KCCHSD continue to achieve our goals of providing high quality patient care, patient experience and outcomes.

Howard commented that the decision was made to include Centura because, like many rural hospitals, Kit Carson County Memorial Hospital simply needed help to keep its doors open, particularly in the COVID-19 pandemic. While the quality of service has never been affected, maintaining a hospital is anything but cheap.

The rural healthcare landscape is complex and seeing rapid change; moreso now than any time in our history. The industry has seen over 100 independent critical access hospitals in communities just like ours across the country struggle to the point of closing the doors since 2010, with more than 600 rural hospitals vulnerable to closure today, Howard pointed out. The challenges brought on by the COVID-19 pandemic will only increase that for many rural hospitals. Many of the critical access hospitals that are surviving today are partnering with a larger organization or system to give them additional layers of support and help.

Neff added, What we do well is understand the needs of the rural community, Neff stated, adding that Centura is able to translate bigger systems into a local level is key to the success of such a union. He noted that it allows staunchly independent rural hospitals to maintain their independence while maintaining the highest quality of health care.

Stability can be a physical thing and an emotional thing. They are looking for both, Neff continued.

Read more:
In a union centered around longevity, Centura Health has joined forces with the Kit Carson County Health Services District (KCCHSD). - Burlington...

Overview for Longevity and Anti-senescence Therapy Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

Longevity and Anti-senescence Therapy Market Data and Acquisition Research Study with Trends and Opportunities 2019-2024The study of Longevity and Anti-senescence Therapy market is a compilation of the market of Longevity and Anti-senescence Therapy broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Longevity and Anti-senescence Therapy industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Longevity and Anti-senescence Therapy industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Download PDF Sample of Longevity and Anti-senescence Therapy Market report @ https://hongchunresearch.com/request-a-sample/113635

Key players in the global Longevity and Anti-senescence Therapy market covered in Chapter 4:Acorda TherapeuticsUnity BiotechnologyAntoxereneCelgeneCohbarSenex BiotechnologyHuman Longevity Inc.T.A. SciencesAgex TherapeuticsRecursion PharmaceuticalsCalico Life SciencesSpotlight BiosciencePowervision Inc.Sierra Sciences LlcRestorbioInsilico MedicineOisin BiotechnologySenolytic TherapeuticsProteostasis Therapeutics Inc.Prana Biotechnology Ltd.Cleara Biotech

In Chapter 11 and 13.3, on the basis of types, the Longevity and Anti-senescence Therapy market from 2015 to 2026 is primarily split into:Senolytic Drug TherapyGene TherapyImmunotherapyOthers

In Chapter 12 and 13.4, on the basis of applications, the Longevity and Anti-senescence Therapy market from 2015 to 2026 covers:LongevitySenescence InhibitionCardiovascular DiseasesNeural Degenerative DiseasesOphthalmology DisordersCancer

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthersRegional scope can be customized

For a global outreach, the Longevity and Anti-senescence Therapy study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

Brief about Longevity and Anti-senescence Therapy Market Report with [emailprotected]https://hongchunresearch.com/report/longevity-and-anti-senescence-therapy-market-size-2020-113635

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Longevity and Anti-senescence Therapy Market

Chapter Four: Players Profiles

Chapter Five: Global Longevity and Anti-senescence Therapy Market Analysis by Regions

Chapter Six: North America Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Seven: Europe Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Eight: Asia-Pacific Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Nine: Middle East and Africa Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Ten: South America Longevity and Anti-senescence Therapy Market Analysis by Countries

Chapter Eleven: Global Longevity and Anti-senescence Therapy Market Segment by Types

Chapter Twelve: Global Longevity and Anti-senescence Therapy Market Segment by Applications 12.1 Global Longevity and Anti-senescence Therapy Sales, Revenue and Market Share by Applications (2015-2020) 12.1.1 Global Longevity and Anti-senescence Therapy Sales and Market Share by Applications (2015-2020) 12.1.2 Global Longevity and Anti-senescence Therapy Revenue and Market Share by Applications (2015-2020) 12.2 Longevity Sales, Revenue and Growth Rate (2015-2020) 12.3 Senescence Inhibition Sales, Revenue and Growth Rate (2015-2020) 12.4 Cardiovascular Diseases Sales, Revenue and Growth Rate (2015-2020) 12.5 Neural Degenerative Diseases Sales, Revenue and Growth Rate (2015-2020) 12.6 Ophthalmology Disorders Sales, Revenue and Growth Rate (2015-2020) 12.7 Cancer Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Longevity and Anti-senescence Therapy Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/113635

List of tablesList of Tables and Figures Table Global Longevity and Anti-senescence Therapy Market Size Growth Rate by Type (2020-2026) Figure Global Longevity and Anti-senescence Therapy Market Share by Type in 2019 & 2026 Figure Senolytic Drug Therapy Features Figure Gene Therapy Features Figure Immunotherapy Features Figure Others Features Table Global Longevity and Anti-senescence Therapy Market Size Growth by Application (2020-2026) Figure Global Longevity and Anti-senescence Therapy Market Share by Application in 2019 & 2026 Figure Longevity Description Figure Senescence Inhibition Description Figure Cardiovascular Diseases Description Figure Neural Degenerative Diseases Description Figure Ophthalmology Disorders Description Figure Cancer Description Figure Global COVID-19 Status Overview Table Influence of COVID-19 Outbreak on Longevity and Anti-senescence Therapy Industry Development Table SWOT Analysis Figure Porters Five Forces Analysis Figure Global Longevity and Anti-senescence Therapy Market Size and Growth Rate 2015-2026 Table Industry News Table Industry Policies Figure Value Chain Status of Longevity and Anti-senescence Therapy Figure Production Process of Longevity and Anti-senescence Therapy Figure Manufacturing Cost Structure of Longevity and Anti-senescence Therapy Figure Major Company Analysis (by Business Distribution Base, by Product Type) Table Downstream Major Customer Analysis (by Region) Table Acorda Therapeutics Profile Table Acorda Therapeutics Production, Value, Price, Gross Margin 2015-2020 Table Unity Biotechnology Profile Table Unity Biotechnology Production, Value, Price, Gross Margin 2015-2020 Table Antoxerene Profile Table Antoxerene Production, Value, Price, Gross Margin 2015-2020 Table Celgene Profile Table Celgene Production, Value, Price, Gross Margin 2015-2020 Table Cohbar Profile Table Cohbar Production, Value, Price, Gross Margin 2015-2020 Table Senex Biotechnology Profile Table Senex Biotechnology Production, Value, Price, Gross Margin 2015-2020 Table Human Longevity Inc. Profile Table Human Longevity Inc. Production, Value, Price, Gross Margin 2015-2020 Table T.A. Sciences Profile Table T.A. Sciences Production, Value, Price, Gross Margin 2015-2020 Table Agex Therapeutics Profile Table Agex Therapeutics Production, Value, Price, Gross Margin 2015-2020 Table Recursion Pharmaceuticals Profile Table Recursion Pharmaceuticals Production, Value, Price, Gross Margin 2015-2020 Table Calico Life Sciences Profile Table Calico Life Sciences Production, Value, Price, Gross Margin 2015-2020 Table Spotlight Bioscience Profile Table Spotlight Bioscience Production, Value, Price, Gross Margin 2015-2020 Table Powervision Inc. Profile Table Powervision Inc. Production, Value, Price, Gross Margin 2015-2020 Table Sierra Sciences Llc Profile Table Sierra Sciences Llc Production, Value, Price, Gross Margin 2015-2020 Table Restorbio Profile Table Restorbio Production, Value, Price, Gross Margin 2015-2020 Table Insilico Medicine Profile Table Insilico Medicine Production, Value, Price, Gross Margin 2015-2020 Table Oisin Biotechnology Profile Table Oisin Biotechnology Production, Value, Price, Gross Margin 2015-2020 Table Senolytic Therapeutics Profile Table Senolytic Therapeutics Production, Value, Price, Gross Margin 2015-2020 Table Proteostasis Therapeutics Inc. Profile Table Proteostasis Therapeutics Inc. Production, Value, Price, Gross Margin 2015-2020 Table Prana Biotechnology Ltd. Profile Table Prana Biotechnology Ltd. Production, Value, Price, Gross Margin 2015-2020 Table Cleara Biotech Profile Table Cleara Biotech Production, Value, Price, Gross Margin 2015-2020 Figure Global Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Global Longevity and Anti-senescence Therapy Revenue ($) and Growth (2015-2020) Table Global Longevity and Anti-senescence Therapy Sales by Regions (2015-2020) Table Global Longevity and Anti-senescence Therapy Sales Market Share by Regions (2015-2020) Table Global Longevity and Anti-senescence Therapy Revenue ($) by Regions (2015-2020) Table Global Longevity and Anti-senescence Therapy Revenue Market Share by Regions (2015-2020) Table Global Longevity and Anti-senescence Therapy Revenue Market Share by Regions in 2015 Table Global Longevity and Anti-senescence Therapy Revenue Market Share by Regions in 2019 Figure North America Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Europe Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Asia-Pacific Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Middle East and Africa Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure South America Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure North America Longevity and Anti-senescence Therapy Revenue ($) and Growth (2015-2020) Table North America Longevity and Anti-senescence Therapy Sales by Countries (2015-2020) Table North America Longevity and Anti-senescence Therapy Sales Market Share by Countries (2015-2020) Figure North America Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2015 Figure North America Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2019 Table North America Longevity and Anti-senescence Therapy Revenue ($) by Countries (2015-2020) Table North America Longevity and Anti-senescence Therapy Revenue Market Share by Countries (2015-2020) Figure North America Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2015 Figure North America Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2019 Figure United States Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Canada Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Mexico Longevity and Anti-senescence Therapy Sales and Growth (2015-2020) Figure Europe Longevity and Anti-senescence Therapy Revenue ($) Growth (2015-2020) Table Europe Longevity and Anti-senescence Therapy Sales by Countries (2015-2020) Table Europe Longevity and Anti-senescence Therapy Sales Market Share by Countries (2015-2020) Figure Europe Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2015 Figure Europe Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2019 Table Europe Longevity and Anti-senescence Therapy Revenue ($) by Countries (2015-2020) Table Europe Longevity and Anti-senescence Therapy Revenue Market Share by Countries (2015-2020) Figure Europe Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2015 Figure Europe Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2019 Figure Germany Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure UK Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure France Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Italy Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Spain Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Russia Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Asia-Pacific Longevity and Anti-senescence Therapy Revenue ($) and Growth (2015-2020) Table Asia-Pacific Longevity and Anti-senescence Therapy Sales by Countries (2015-2020) Table Asia-Pacific Longevity and Anti-senescence Therapy Sales Market Share by Countries (2015-2020) Figure Asia-Pacific Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2015 Figure Asia-Pacific Longevity and Anti-senescence Therapy Sales Market Share by Countries in 2019 Table Asia-Pacific Longevity and Anti-senescence Therapy Revenue ($) by Countries (2015-2020) Table Asia-Pacific Longevity and Anti-senescence Therapy Revenue Market Share by Countries (2015-2020) Figure Asia-Pacific Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2015 Figure Asia-Pacific Longevity and Anti-senescence Therapy Revenue Market Share by Countries in 2019 Figure China Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Japan Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure South Korea Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Australia Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure India Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Southeast Asia Longevity and Anti-senescence Therapy Sales and Growth Rate (2015-2020) Figure Middle East and Africa Longevity and Anti-senescence Therapy Revenue ($) and Growth (2015-2020) continued

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

https://neighborwebsj.com/

Read this article:
Global Longevity and Anti-senescence Therapy Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based...

There is little chance that anyone in Maryland or anywhere will hold power as long as the late Thomas V. Mike Miller Jr., the former president of the state Senate who died on Friday.

A one-term delegate who won a Senate seat in 1974, Miller ruled the chamber from 1987 to 2019, a tenure widely believed to be the longest in American history.

In a series of interviews conducted byMaryland Matters over the last 18 months, those who served alongside Miller described a complex man of extraordinary talent who had a deep, authentic love for the state and its institutions, particularly the Maryland Senate.

He was a fervent Democrat who believed that government had a role to play in helping those with fewer advantages achieve success, who also understood that the pace of change had to be calibrated to suit a state that is home to both very liberal and very conservative voters.

A gregarious backslapper with a big laugh, Miller dominated large rooms and small. He was a history buff, loyal, true to his word, and a passionate advocate for public education and the Chesapeake Bay. He steered the Senate through recessions, tense policy debates and all manner of crises.

While members of his chamber occasionally got entangled in legal wrongdoing, Miller (to borrow former Virginia Rep. Tom Davis favorite phrase) left office undefeated and un-indicted.

And while the public view of him was as the presiding officer of the Senate, much of the influence he exerted on the states political eco-system occurred off-stage encouraging some candidates to run and connecting them with support, and discouraging others.

Miller was a very loyal, real Democrat, said U.S. House Majority Leader Steny H. Hoyer (D-Md.) in a 2020 interview.

He (was) a more conservative Democrat than some others, but he did not allow that to impede his support for items central to what he believed the Democrat ethos was in terms of helping people whether it be education, health care, social issues.

Although Miller insisted on decorum in the Senate chamber, he was a larger-than-life presence around the State House. Behind closed doors, he deployed a broad mix of skills.His language was often salty.

I never worked with [former president Lyndon Baines Johnson], but I did work with Mike Miller, said former Gov. Martin J. OMalley (D). He was capable of the full range of human emotion and persuasive skills and tactics.

He could be overbearing, hard-charging and threatening in one instant, and he could be kind and listening and compassionate in the next moment. He was not a one-dimensional person by any means, OMalley added. He understood that progress in the public arena is about the art of accomplishing the possible in the moment. That requires persuasion. It requires compromise.

He didnt always win. And sometimes his tactics backfired and caused people to dig in their heels. But in the longer run, weve never had a more successful Senate presidency than his.

Miller: Times change, but people dont

Although there were coup attempts, as colleagues chafed at his longevity, they never got far.

Those who worked closely with Miller said the key to his epic tenure was his uncanny ability to adapt to changing times.

During his 33-year run as the upper chambers presiding officer, Maryland become more diverse racially and more liberal politically, and women began to rise through the ranks.

A history buff who was deeply involved in national legislative organizations, Miller tracked political and policy trend-lines closely. He knew that to stay atop the heap, he had to repositionhimself after every election and sometimes more often than that.

His one major political stumble occurred in 1989, when he told a Washington, D.C., TV reporter in Baltimore that the city was a goddamn ghetto.

He quickly claimed that he used the phrase to show his constituents how dire conditions in the city were. But the damage was done: Any aspirations Miller had for statewide office were extinguished. But his power in Annapolis was never diminished.

In his last in-depth interview, Miller told Maryland Matters in December that his ability to find the new center of the Democratic caucus was the key to his longevity.

I would say [that was] 90% of it, quite frankly. Honestly and truly. I knew where the Senate had been, I knew where the Senate was now, and I could predict where the Senate was going, the lawmaker said.

Times change, but people dont, he added. They make the same mistakes over and over again. And I was determined not to do that. And at the same time recognizing where the demographics of the state are going to take us. Recognizing that the House and Senate need to adjust to accommodate the changing demographics.

U.S. Sen. Chris Van Hollen (D) recalled that when he was running against state Sen. Patricia Sher (D) in the 1994 primary, he received a call from Miller, 10 days before the election, inviting him to breakfast. The call was a surprise, because Miller was backing Sher.

The two met at a posh country club in Montgomery County.

He said, Youre gonna win, Van Hollen said.

Miller asked Van Hollen, then a member of the House of Delegates, what committee assignment he wanted. Budget and Taxation, Van Hollen replied. Done, Miller responded.

The heart of Mikes success, and the fact that he has made such a difference in the history of our state, is his instinctive, tactile sense of politics and where the center of gravity is, and what direction its moving in, Van Hollen asserted.

And his ability to adapt.

In 1996, Van Hollen and another liberal lawmaker, Sen. Paul G. Pinsky (D-Prince Georges), who were first-term senators at the time, nearly derailed a high-profile Miller priority, to bring two new football stadiums to Maryland, in Baltimore and Landover.

Miller was furious, and the back-benchers fell one vote short. But Miller eventually appointed to both to leadership positions.

While Miller is best known for the 33 years he guided the state Senate through its annual 90-day sessions, he also wielded extraordinary power in encouraging candidates up and down the political ladder throughout the state.

Former Prince Georges County Executive Rushern L. Baker III (D) recalled being aghast that he had to get Millers blessing if he hoped to be successful.

And when Baker became chairman of the countys House delegation, the two clashed over a zoning measure Miller was eager to advance.

After the dust-up blew over, Baker came to appreciate Millers skills and the two became close allies.

Once he put his imprimatur on you, you instantly got it didnt mean you were going to win but it meant that you got access to people who could help you, Baker said.

You had access to people with money. You had access to other politicians who would start meeting with you, which is what happened with me. You had access to community groups. You had access to congressmen.

A former two-term county executive, Baker said he frequently leaned on his relationship with and the lessons he learned from Miller.

There is not a single thing I did as county executive that was important and significant that I did not ask his help. And it was given unconditionally. Even if he didnt agree with it and there was a lot that I did that he thought was nuts, Baker recalled with a laugh.

Miller vs. Glendening

Former Gov. Parris N. Glendening (D) rose through the ranks of Prince Georges politics in the 1970s, just as Miller did. But the two were polar opposites.

Glendening was a liberal college professor, bookish and a newcomer to Maryland; Miller was more conservative, more social, and an old-school pol.

In 1974, when he was running for the County Council, Glendening said he was stunned, on election night, when he got more votes in Millers backyard, the southern part of Prince Georges, than he did in the precincts where he was more well-known.

The Miller machine had delivered.

It was a phenomenal demonstration from a political science perspective of how it worked, Glendening said. And it worked in part because people like Mike Miller ran his district.

I was teaching urban politics at the time I was talking [to my students] about urban machines! the former governor added, still amazed by that nights outcome. But I never had actually been involved and saw how smoothly it works.

Despite all the ups and downs, the Maryland Senate, the state of Maryland and the [state] Democratic Party are better off today because Mike Miller devoted his whole life to being president of the Maryland Senate, Glendening added. I feel very strongly about that.

Glendening became governor in 1995, and there was a widespread expectation that the two would clash, because they often did in Prince Georges County.

Miller had made rude comments about Glendening in the media and the pair were not close. Glendenings insistence that he and not the political machine run by Peter OMalley would choose his department heads in Upper Marlboro, had upset the prevailing order.

But the governor said he had a secret weapon once he got to Annapolis his director of legislative affairs, Joseph C. Bryce, who had served as Millers chief of staff. Bryces advice was simple: Attach any policy initiative to one of Millers three loves the state of Maryland, the state Senate or the Democratic Party.

The strategy worked and the expected ill will rarely materialized.

What has saved him from becoming his own worst enemy at times is that he has been so effective, Glendening said. And even if you dont like him, and even if youre the focus of some of his explosiveness and comments and all, as I have been, you still have to take one step back and say wow, he is effective.

A man of his word

Baker, Glendening and others said that when Miller gave his word on something, you could take it to the bank.

The thing I like about Miller is when he said yes, it was real yes, said Baker. It wasnt yes and good luck. You didnt have to check his pulse. It didnt matter how many enemy were coming over [the wall], he was there.

He was going to berate you. He was going to beat you up. He was going to test your commitment to this crazy idea that you had, Baker added. But he wasnt going to abandon you. He would yell at me in ways I just found so offensive, for a grown man with three children and a law degree, but I never felt abandoned.

Baker said Miller was particularly tough on him when he sought reforms in the countys education system.

He would say youre weak, youre a sorry leader. Itll never get done. You asked for this crazy s and I told you not to do it and you did it anyway. So youre going to be fed and all this stuff. And then at the end, hed pat you on the back and say, well make it happen. Dont worry, Baker, were gonna make it happen. And hed walk out!

Hoyer, whose rise through Maryland politics coincided with Millers, said the late Senate president got his outspokenness from his mother, Esther Miller. He gets great values [from his mother] a deep sense of duty and empathy for people that sometimes is hard to find or you wouldnt think that that would be part of his personality, because of his gruffness.

Mike is very smart. Very tough. Very candid. He can be vulgar at times, ribald at times, Hoyer added. He can be very gruff, as you know. And also very funny. But also biting. But again, all of that is on the surface. And underneath is this really deep sense of fairness and of wanting to make sure that people have a shot in life and have help in life.

Several times during his epic tenure, Miller allowed legislation that he opposed personally to come to the floor. Measures allowing an abortion-rights referendum, a gay marriage referendum and the death penalty repeal were the most prominent.

Those who worked with him say his unwillingness to shelve policy that has ripe was primary to his long hold on power.

Mike is always 10 steps ahead of everybody else, Van Hollen said last year.

Here you have a Senate president from Southern Maryland a relatively conservative part of our state who has presided over a state that is one of the most progressive in the country. And that is really a testament to his both political sense but also his historical sense of where were heading, Van Hollen said.

We have a way of turning our leaders into cartoons, said OMalley. But Mike Miller was not a cartoon. He was a guy with an appreciation of history, a love of our state, an understanding of human nature, and the capacity to be tough when he needed to be tough and to be understanding and listening and accommodating when that was what the mission called for.

[emailprotected]

More here:
'He Was Capable of the Full Range of Human Emotion and Persuasive Skills and Tactics' Maryland Matters - Josh Kurtz

President Joe Biden announced on Wednesday night that he plans to issue a regulatory freeze on many of former President Donald Trump's last-minute new or pending rules.

The freeze is likely to affect a variety of much-publicized U.S. Department of Health and Human Services rulemakings including proposed major HIPAA Privacy Rule changes, mandated regulatory reviews and efforts to streamline interoperability and prior authorization.

The Biden administration also announced a flurry of new HHS and other health-related hires, heralding a major overhaul for the agency.

HIMSS20 Digital

WHY IT MATTERS

Trump's HHS enacted several rules after the former president lost the 2020 election, raising questions even at the time of their longevity.

Biden's freeze will hit pause on several of them, at least for the time being.

According to a memo sent last night, the heads of executive departments and agencies are to propose or issue no rule in any manner until a Biden-appointed department head reviews and approves it.

The memo also directs decision-makers to withdraw any rule sent to the Office of the Federal Register but not published, which would appear to apply to a recently finalized prior authorization and interoperability rule.

With respect to rules that have been published but have yet to take effect, such as the mandated once-a-decade regulatory reviews and proposed HIPAA changes, the Biden memo directs leaders to "consider postponing the rules' effective dates for 60 days" and "consider opening a 30-day comment period," as well as implementing additional delays if necessary.

This section appears to apply to last-minute rules that would rescind the U.S. Food and Drug Authority's ability to regulate a number of medical devices.

The memo came amid several high-profile agency hires also announced on Inauguration Day.

These include the appointment of Micky Tripathi as the new National Coordinator for Health IT.

Elizabeth Richter will serve as acting administrator for the Centers for Medicare and Medicaid Services, pending Senate confirmation of a permanent administrator.

Norris Cochran will serve as acting HHS secretary pending Biden Nominee Xavier Becerra's Senate approval.

Perryn Ashmore, who was appointed as acting HHS chief information officer in September 2020, looks to be continuing in that role for now.

Other hires include Sean McCluskie as HHS chief of staff,Topher Spiro as head of health programs at the Office of Management and Budget,and Sarah Despres as a counselor to new HHS Secretary Xavier Becerra.

According to PoliticoPro, Anne Reid will be HHS deputy chief of staff,Lisa Barclay and Paul Rodriguez will be deputy general counsels,Josh Peck will be deputy assistant secretary for public engagement,and Kristin Avery will be White House liaison.

THE LARGER TREND

All eyes are on Biden's health policy moves as he takes office specifically, his plans to roll out a COVID-19 vaccine.

The rollout under Trump's administration faced several logistical and infrastructure hurdles, with states left to their own devices to schedule and allocate vaccines.

It remains to be seen whether Biden can right the ship.

ON THE RECORD

"We are in a race against time, and absent additional government assistance, the economic and public health crises could worsen in the months ahead; schools will not be able to safely reopen; and vaccinations will remain far too slow," said Biden in the COVID-19 relief package published to his website this past week.

Kat Jercich is senior editor of Healthcare IT News.Twitter: @kjercichEmail: kjercich@himss.orgHealthcare IT News is a HIMSS Media publication.

The rest is here:
Biden plans regulatory freeze amid flurry of health hires - Healthcare IT News